Methylation of the MGMT promoter is utilized as a biomarker to predict clinical response to a chemotherapeutic agent in glioma (53).With regard to MYO1G, cg10673833 located on MYO1G promoter region was reported to be a biomarker in the diagnosis and disease monitoring of colorectal cancer (22). This evidence concerns the gene MYO1G and colorectal cancer.